# A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

> **NCT00048165** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 434 (actual)

## Conditions studied

- Heart Transplantation

## Interventions

- **DRUG:** Daclizumab
- **DRUG:** Methylprednisolone
- **DRUG:** Mycophenolate mofetil
- **DRUG:** Placebo
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT00048165
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-08
- **Primary completion:** 2002-08
- **Final completion:** 2002-08
- **Target enrollment:** 434 (ACTUAL)
- **Last updated:** 2016-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048165, "A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00048165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*